Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Novello1, F. Barlesi2, R. Califano3,4, T. Cufer5, S. Ekman6, M. Giaj Levra7, K. Kerr8, S. Popat9, M. Reck10, S. Senan11, G. V. Simo12, J. Vansteenkiste13 & S. Peters14 on behalf of the ESMO Guidelines Committee* Oncology Department, University of Turin, AOU San Luigi-Orbassano, Orbassano, Italy; Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Marseille, France; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; Medical Faculty Ljubljana, University Clinic Golnik, Golnik, Slovenia; Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Thoracic Oncology Unit, Centre Hospitalier Universitaire Grenoble Alpes (CHUGA), Grenoble, France; Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen; Department of Medicine, Royal Marsden Hospital, London, UK; Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Centre for Lung Research (DZL), Grosshansdorf, Germany; Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands; Thoracic Surgery Service, Salamanca University Hospital, Salamanca, Spain; Respiratory Oncology Unit (Pulmonology), University Hospital KU Leuven, Leuven, Belgium; Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

[1]  R. Freeman,et al.  The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[3]  G. Giaccone,et al.  Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States , 2015, Front. Oncol..

[4]  M. Kamdar,et al.  Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Wahidi,et al.  Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[6]  C. la Vecchia,et al.  Risk factors for lung cancer worldwide , 2016, European Respiratory Journal.

[7]  P. Ascierto,et al.  Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  G. Varela,et al.  Surgical management of oligometastatic non-small cell lung cancer. , 2016, Journal of thoracic disease.

[10]  J. Lester,et al.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. , 2015, The Cochrane database of systematic reviews.

[11]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[12]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[15]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[16]  B. Uzzan,et al.  Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. , 2012, Critical reviews in oncology/hematology.

[17]  Rolf Kaiser,et al.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.

[18]  S. Edge,et al.  AJCC Cancer Staging Handbook, 6th edition , 2002 .

[19]  A. Wolf,et al.  Extrapleural pneumonectomy for pleural malignancies. , 2014, Thoracic surgery clinics.

[20]  Jeffrey W. Scott,et al.  ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Michael Thomas,et al.  Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial , 2016, The Lancet. Oncology.

[22]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[23]  F. Thunnissen,et al.  A prospective study of the timing and cost-effectiveness of bronchial washing during bronchoscopy for pulmonary malignant tumors. , 2005, Chest.

[24]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[25]  A. Gemma,et al.  First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Sang Min Lee,et al.  C-arm cone-beam CT-guided percutaneous transthoracic needle biopsy of lung nodules: clinical experience in 1108 patients. , 2014, Radiology.

[27]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[28]  J. Pignon,et al.  Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  F. Shepherd,et al.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. O'Byrne,et al.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.

[31]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Beyene,et al.  Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. , 2015, International journal of radiation oncology, biology, physics.

[33]  D. Serraino,et al.  Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy , 2007, Cancer.

[34]  P. Shah,et al.  Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis , 2009, Thorax.

[35]  Darragh G. McArt,et al.  Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis , 2013, PloS one.

[36]  A. Nicholson,et al.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[37]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[38]  C. Dooms,et al.  Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group , 2015, Thorax.

[39]  Xin-ji Zhang,et al.  Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. , 2011, Chest.

[40]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[41]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[42]  Tarek Mekhail,et al.  Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study , 2011, Current oncology reports.

[43]  O. Molinier,et al.  Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. , 2016 .

[44]  Y. Soon,et al.  Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. , 2014, The Cochrane database of systematic reviews.

[45]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[46]  T. Ciuleanu,et al.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.

[47]  M. Socinski,et al.  Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[49]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[50]  Yang Zhao,et al.  Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls , 2012, Human molecular genetics.

[51]  T. Kohno,et al.  Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. , 2017, The Lancet. Respiratory medicine.

[52]  G. Fasola,et al.  Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. , 2009, The oncologist.

[53]  Jeffrey W. Clark,et al.  Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). , 2017 .

[54]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[55]  G. Lillington,et al.  Management of the solitary pulmonary nodule. , 1993, Hospital practice.

[56]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[57]  R. Riera,et al.  Chemotherapy for advanced non-small cell lung cancer in the elderly population , 2016, Sao Paulo medical journal = Revista paulista de medicina.

[58]  G. Scagliotti,et al.  Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  B. Milleron,et al.  Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). , 2010, Lung cancer.

[60]  M. Ladanyi,et al.  Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  R. Morice,et al.  Original Research: Lung CancerSmoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status , 2006 .

[62]  S. Moolgavkar,et al.  Chapter 6: Lung Cancer in Never Smokers: Epidemiology and Risk Prediction Models , 2012, Risk analysis : an official publication of the Society for Risk Analysis.

[63]  A. Gemma,et al.  First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. Gridelli,et al.  Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Groen,et al.  Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. , 2017 .

[67]  K. Kelly,et al.  The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  L. Zeng,et al.  Update on the systematic review of palliative radiotherapy trials for bone metastases. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[69]  A. Rossi,et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.

[70]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[71]  P. Starostik,et al.  Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. , 2015, Archives of pathology & laboratory medicine.

[72]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[73]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Pignon,et al.  Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. , 2004, JAMA.

[75]  Kwok-Kin Wong,et al.  Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.

[76]  P. Woll,et al.  Quality of life, support and smoking in advanced lung cancer patients: a qualitative study , 2014, BMJ Supportive & Palliative Care.

[77]  R. Morice,et al.  Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. , 2006, Chest.

[78]  Hermann Brenner,et al.  Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. , 2007, The Lancet. Oncology.

[79]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  D. Costa,et al.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. , 2015, Lung cancer.

[81]  M. Socinski,et al.  IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. , 2018, Journal of Clinical Oncology.

[82]  A. Tsao.  Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial , 2012 .

[83]  F. Bidault,et al.  Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. , 2018, European journal of cancer.

[84]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[85]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[86]  S. Gettinger,et al.  ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) , 2016 .

[87]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[89]  R. Agarwal,et al.  Pleurodesis for malignant pleural effusions. , 2013, The Cochrane database of systematic reviews.

[90]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[91]  Recinda L. Sherman,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival , 2017, Journal of the National Cancer Institute.

[92]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[94]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[95]  M. Ladanyi,et al.  Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.

[96]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[97]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[98]  C. Gridelli,et al.  Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  J. Daurès,et al.  Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  F. Greene.  AJCC cancer staging handbook , 2002 .

[101]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[102]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[103]  G. Scagliotti,et al.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[104]  J. Mosser,et al.  EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice , 2017, European Respiratory Journal.

[105]  A. Tafreshi,et al.  Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. , 2017, The Lancet. Oncology.

[106]  Bastien Cabarrou,et al.  Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[107]  A. Hoos,et al.  1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  E. Chae,et al.  Percutaneous CT-guided aspiration and core biopsy of pulmonary nodules smaller than 1 cm: analysis of outcomes of 305 procedures from a tertiary referral center. , 2013, AJR. American journal of roentgenology.

[109]  E. Felip,et al.  Symptom and Quality of Life Improvement in LUX‐Lung 8, an Open‐Label Phase III Study of Second‐Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First‐Line Platinum‐Based Chemotherapy , 2018, Clinical lung cancer.

[110]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[111]  L. Ger,et al.  [Risk factors of lung cancer]. , 1992, Journal of the Formosan Medical Association = Taiwan yi zhi.

[112]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  F. Cappuzzo,et al.  Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. , 2017, Lung cancer.

[114]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[115]  Nicholas B. Levine,et al.  Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[116]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[117]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[118]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[119]  Yi-long Wu,et al.  Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). , 2016, Lung cancer.

[120]  N. Chaput,et al.  Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? , 2017, Cancer treatment reviews.

[121]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[122]  Koichi Goto,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.

[123]  Paolo Battistoni,et al.  Endobronchial ultrasound-driven biopsy in the diagnosis of peripheral lung lesions. , 2005, Chest.

[124]  You Lu,et al.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. , 2015, The Lancet. Oncology.

[125]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[126]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[127]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Satoshi Suzuki,et al.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.

[129]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[130]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[131]  P. Brown,et al.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. , 2013, Neuro-oncology.

[132]  C. la Vecchia,et al.  The global decrease in cancer mortality: trends and disparities. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  Umberto Ricardi,et al.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. , 2014, Clinical lung cancer.

[134]  C. Dooms,et al.  Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[135]  E. Rakovitch,et al.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. , 2018, The Cochrane database of systematic reviews.

[136]  R. Davies,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[137]  A. Rossi,et al.  Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. , 2014, The Lancet. Oncology.

[138]  O. Ganslandt,et al.  Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[139]  M. Ladanyi,et al.  Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[141]  Ruth E Langley,et al.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.

[142]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[143]  C. Gridelli,et al.  A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study , 2004, British Journal of Cancer.

[144]  M. Kris,et al.  A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. , 2002, Lung cancer.

[145]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[146]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[147]  A. Marchetti,et al.  Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment , 2014, PloS one.

[148]  S. Hahn,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. , 2014, JAMA.

[149]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[150]  William S. Bush,et al.  Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes , 2017, Nature Genetics.

[151]  K. Black,et al.  Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. , 2017, The Cochrane database of systematic reviews.

[152]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[153]  Keunchil Park,et al.  Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR. , 2016 .

[154]  P. V. Van Schil,et al.  Salvage Operation in Case of Oligometastatic Disease. , 2017, The Annals of thoracic surgery.

[155]  P. V. Van Schil,et al.  Salvage surgery after high-dose radiotherapy. , 2017, Journal of thoracic disease.

[156]  T. Wilt,et al.  Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomised trials. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[157]  K. Blackwell,et al.  Leptomeningeal disease: current diagnostic and therapeutic strategies , 2017, Oncotarget.

[158]  M. Fukuoka,et al.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[160]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[161]  J. Daurès,et al.  Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. , 2006, Lung cancer.

[162]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[163]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2017, with focus on lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[164]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[165]  M. Parmar,et al.  Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). , 2015 .

[166]  P. A. van den Brandt,et al.  Association between Cigar or Pipe Smoking and Cancer Risk in Men: A Pooled Analysis of Five Cohort Studies , 2017, Cancer Prevention Research.

[167]  U. Dafni,et al.  Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Respiratory medicine.

[168]  K. Hemminki,et al.  Familial Lung Cancer and Aggregation of Smoking Habits: A Simulation of the Effect of Shared Environmental Factors on the Familial Risk of Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[169]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[170]  Edward S. Kim,et al.  Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. , 2018 .

[171]  M. Ahn,et al.  First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. , 2016, JAMA oncology.

[172]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[173]  T. Mitsudomi,et al.  A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[174]  P. Goldstraw,et al.  Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[175]  G. Ferretti,et al.  Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial. , 2015 .

[176]  S. Novello,et al.  OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC , 2018, Journal of Thoracic Oncology.

[177]  B. Milleron,et al.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.

[178]  C. Barrios,et al.  Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[180]  E. Scalzetti,et al.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. , 2005, Chest.

[181]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[182]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[183]  A. Gemma,et al.  Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). , 2018 .

[184]  A. Nicholson,et al.  A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[185]  M. Socinski,et al.  Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer , 2015, The Lancet. Oncology.

[186]  B. Milleron,et al.  Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  K. O'Byrne,et al.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  T. Yamanaka,et al.  Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. , 2018 .

[189]  L. Thiberville,et al.  Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[190]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[192]  C. Obasaju,et al.  PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  M. Soda,et al.  Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[194]  L. Bubendorf,et al.  Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC). , 2017 .

[195]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[196]  G. Scagliotti,et al.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors , 2014, Supportive Care in Cancer.

[197]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[198]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[199]  F. Hodi,et al.  Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? , 2014, Journal of Immunotherapy for Cancer.

[200]  B. Taylor,et al.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.

[201]  William Wheeler,et al.  Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer , 2014, Nature Genetics.

[202]  M. Ahn,et al.  Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[204]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[205]  T. Treasure,et al.  The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[206]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[207]  M. Socinski,et al.  Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[208]  M. Chamberlain,et al.  Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[209]  A. Reissig,et al.  Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[210]  Keunchil Park,et al.  Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. , 2017 .

[211]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  J. Soria,et al.  Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[213]  Vamsidhar Velcheti,et al.  HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[214]  S. Khozin,et al.  Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial. , 2016 .

[215]  A. Gemma,et al.  F1000 highlights , 2010 .

[216]  Rolf Kaiser,et al.  Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. , 2015, European journal of cancer.

[217]  A. Shaw,et al.  Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.

[218]  A. Chacko,et al.  Interventions for the treatment of metastatic extradural spinal cord compression in adults. , 2008, The Cochrane database of systematic reviews.

[219]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[220]  Roman K. Thomas,et al.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  J. Wolchok,et al.  The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. , 2008, Cancer immunity.

[222]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[223]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[224]  F. Herth,et al.  Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial. , 2004, Chest.

[225]  T. Tojo,et al.  Institutional report - Thoracic oncologic Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination , 2010 .

[226]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[227]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[228]  A. Marchetti,et al.  Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[229]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[230]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[231]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[232]  T. Mok,et al.  Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. , 2018, Journal of Clinical Oncology.

[233]  Edina M K da Silva,et al.  Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. , 2013, The Cochrane database of systematic reviews.

[234]  D. Ball,et al.  Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer , 2016, Asia-Pacific journal of clinical oncology.

[235]  A. Gregor,et al.  Imaging features of leptomeningeal metastases. , 1999, Clinical radiology.

[236]  L. Breslow,et al.  Air pollution and cancer. , 1960, Proceedings. National Cancer Conference.

[237]  S. Novello,et al.  Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[238]  Ronald Brand,et al.  Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery , 1993, Annals of neurology.

[239]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[240]  N. Pavlakis,et al.  ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC , 2018, Pneumologie.

[241]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[242]  Jayne Tierney,et al.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[243]  D. Theegarten,et al.  Surgery of Primary Lung Cancer with Oligometastatic M1b Synchronous Single Brain Metastasis: Analysis of 37 Cases , 2014, Thoracic and Cardiovascular Surgeon.

[244]  M. Ahn,et al.  CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). , 2017 .

[245]  L. Sequist,et al.  First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[246]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[247]  H. Zhang,et al.  BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[248]  H. Groen,et al.  Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[249]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[251]  B. Burnand,et al.  Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. , 2008, Lung cancer.

[252]  Hyae-Young Kim,et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  Xiaohua Liang,et al.  A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. , 2007, Lung cancer.

[254]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[255]  F. Cappuzzo,et al.  Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[256]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[257]  U. Dafni,et al.  A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. , 2017 .

[258]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[259]  G. Duncan,et al.  A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis , 1996, Cancer.

[260]  A. Nakagawara,et al.  Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. , 2011, Chest.

[261]  M. Hubka,et al.  Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study. , 2015, The Annals of thoracic surgery.

[262]  Y. Shentu,et al.  Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. , 2017 .

[263]  C. Blakely,et al.  Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. , 2012, Cancer discovery.

[264]  Y. Shentu,et al.  OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab , 2017 .

[265]  C. Schumann,et al.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. , 2015, The Lancet. Oncology.

[266]  M. Mehta,et al.  Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  D. Ball.  The IASLC multidisciplinary approach to thoracic oncology. , 2014 .

[268]  S. Burdett.  Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. , 2008, The Cochrane database of systematic reviews.

[269]  F. Hirsch,et al.  IASLC ATLAS OF EGFR TESTING IN LUNG CANCER , 2017 .

[270]  A. Giobbie-Hurder,et al.  Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.

[271]  P. Jänne,et al.  Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas , 2014, European Respiratory Review.

[272]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[273]  Rosa M. Estrada-Y.-Martin,et al.  Diagnostic Yield and Complications of Bronchoscopy for Peripheral Lung Lesions. Results of the AQuIRE Registry. , 2016, American journal of respiratory and critical care medicine.

[274]  Masahiko Ando,et al.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[275]  E. Smit,et al.  Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[276]  David M. Hyman,et al.  The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. , 2017 .

[277]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[278]  Yang Yao,et al.  Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2012, Lung.

[279]  A. Sasse,et al.  Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2010, PloS one.

[280]  D. Dunlop,et al.  Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[281]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[282]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[283]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[284]  J. Ahn,et al.  Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[285]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[286]  Ross Camidge,et al.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[287]  H. Baumel,et al.  Results of Therapy , 1986 .

[288]  Martin Marciniak,et al.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[289]  G. Giaccone,et al.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.

[290]  A. Shaw,et al.  Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[291]  A. Hofman,et al.  Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium , 2016, BMC Medicine.

[292]  A. Drilon,et al.  Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors , 2015, Proceedings of the National Academy of Sciences.

[293]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[294]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[295]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[296]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[297]  F. Detterbeck,et al.  Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[298]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[299]  Jeffrey W. Clark,et al.  Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). , 2016 .

[300]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[301]  Benjamin Solomon,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[302]  M. Soda,et al.  EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration , 2010, Clinical Cancer Research.

[303]  F. Hirsch,et al.  Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? , 2016, Archives of pathology & laboratory medicine.

[304]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[305]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[306]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[307]  Stina W. Andersen,et al.  A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. , 2017, The Annals of thoracic surgery.

[308]  Joe Y. Chang,et al.  Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer , 2013, Cancer.

[309]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[310]  A. Shaw,et al.  MA07.11 Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC) , 2017 .

[311]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[312]  A. Jemal,et al.  Increasing lung cancer death rates among young women in southern and midwestern States. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[313]  A. Drilon,et al.  A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. , 2018 .

[314]  F Levi,et al.  European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[315]  S. Peters,et al.  Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. , 2014, Cancer treatment reviews.

[316]  C. Gridelli,et al.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. , 2012, The Lancet. Oncology.

[317]  H. Blanché,et al.  BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers , 2015, European Respiratory Journal.

[318]  A. Gemma,et al.  Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[319]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[320]  G. Pershagen,et al.  Air pollution and cancer. , 1990, IARC scientific publications.

[321]  M. Maemondo,et al.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[322]  A. Gemma,et al.  Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. , 2018 .

[323]  Yi-long Wu,et al.  Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. , 2014, Lung cancer.

[324]  J. Sørensen,et al.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. , 2012, Lung cancer.

[325]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[326]  R. Govindan,et al.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[327]  F. Bray,et al.  Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007 , 2010, International journal of cancer.

[328]  A. Cardona,et al.  Palliative endobronchial brachytherapy for non-small cell lung cancer. , 2008, Cochrane Database of Systematic Reviews.

[329]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[330]  L. C. Swenson,et al.  MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. , 1994, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[331]  Joon-Oh Park,et al.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[332]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[333]  W. Wick,et al.  Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma , 2016, Molecular Cancer Therapeutics.

[334]  M. Kris,et al.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[335]  Jie Yang,et al.  Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[336]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[337]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[338]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[339]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[340]  A. Redig,et al.  Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. , 2017, Cancer research.

[341]  H. Groen,et al.  Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[342]  G. Ferretti,et al.  Negative Predictive Value of Transthoracic Core-Needle Biopsy: A Multicenter Study. , 2015, Chest.

[343]  A. Shaw,et al.  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine , 2015, Clinical Cancer Research.

[344]  C. Lequaglie,et al.  What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. , 2015, Critical reviews in oncology/hematology.

[345]  J. Soria,et al.  Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study , 2015, Clinical Cancer Research.

[346]  T. Mok,et al.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.

[347]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[348]  Y. Ung,et al.  Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[349]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[350]  T. Yamanaka,et al.  Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). , 2016 .

[351]  D. Mavroudis,et al.  Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study , 2013, Cancer.

[352]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[353]  Xiangdong Zhou,et al.  Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[354]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[355]  W. Oyen,et al.  PET in the management of locally advanced and metastatic NSCLC , 2015, Nature Reviews Clinical Oncology.

[356]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[357]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[358]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[359]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[360]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[361]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[362]  C. McArdle,et al.  An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer , 2005, British Journal of Cancer.

[363]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[364]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[365]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[366]  S. Novello,et al.  1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC , 2017 .

[367]  K. O'Byrne,et al.  Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[368]  P. F. Kauff.  Group , 2000, Elegant Design.

[369]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[370]  A. Tafreshi,et al.  OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% , 2017 .

[371]  J. Wolchok,et al.  Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[372]  J. Siegfried,et al.  Gender-Related Differences in Lung Cancer , 2018 .

[373]  J. Y. Lee,et al.  A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[374]  Han Wu,et al.  Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small‐cell lung cancer patients , 2013, International journal of cancer.

[375]  Ji-An Liang,et al.  Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. , 2012, Academic radiology.

[376]  M. Mason,et al.  Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. , 2003, The Cochrane database of systematic reviews.

[377]  L. Bubendorf,et al.  Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients , 2016, Journal of Thoracic Oncology.

[378]  K. Kerr,et al.  Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[379]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[380]  Qian Zhang,et al.  Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials , 2012, PloS one.

[381]  J. Kollmeier,et al.  Metastasectomy for synchronous solitary non-small cell lung cancer metastases. , 2014, The Annals of thoracic surgery.

[382]  Matthew D. Hellmann,et al.  Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 , 2018, Clinical Trials.

[383]  B. Milleron,et al.  Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy , 2016, European Respiratory Journal.

[384]  M. Ridder,et al.  Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[385]  B. V. Van Beers,et al.  Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. , 2018, European journal of cancer.

[386]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[387]  M. Burt,et al.  Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. , 1992, The Journal of thoracic and cardiovascular surgery.

[388]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[389]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[390]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[391]  A. Marchetti,et al.  ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[392]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[393]  S. Fujita,et al.  CT-guided fine-needle aspiration and core needle biopsies of pulmonary lesions: a single-center experience with 750 biopsies in Japan. , 2015, AJR. American journal of roentgenology.